Shire is looking for opportunities in Central Nervous System (CNS) / Neuropsychiatry, Gastrointestinal, Orphan genetic diseases, Allergy and Hematology
Shire Pharmaceuticals Group, Plc
Shire Pharmaceuticals is a rapidly growing, international specialty biopharmaceutical company. Shire’s development focus is in central nervous system disorders, gastro-intestinal, regenerative medicine, human genetic therapies and orphan diseases. Shire has completed nine mergers and acquisitions in eleven years. In-licensing and product acquisitions are a priority at Shire.
The SIG is Shire’s corporate venture fund, tasked with identifying and investing in external innovation that may bring new products to Shire’s pipeline and which support Shire’s overall mission to enable people with life-altering conditions to lead better lives.
Further to that mission, Shire is focused on delivering novel, cost-effective therapies to patients with symptomatic diseases and significant unmet medical need.
Accordingly, the SIG seeks to invest across a broad range of therapeutic areas of interest including, but not limited to, the following:
- Central Nervous System (CNS) / Neuropsychiatry
- Orphan genetic diseases
The SIG also pursues investments in “white space” technology – areas outside the traditional bounds of its existing businesses.
Depending upon the indication, collaborations may be formed at various stages of the development process.